Author(s): Guillot B
Innovations in dermatological therapy remain rare. In 2013, increase in the knowledge of mechanism of action and place in the therapeutic strategies concern some recent drugs. For psoriasis treatment, efficacy and safety of anti IL-17 and anti JAK pathway has been demonstrated in randomized studies versus placebo. In other inflammatory diseases, the role of rituximab in auto immune bullous diseases and of omalizumab in chronic urticaria is better known. This year was published the first randomized trial using anti TNF in hidradenitis suppurativa with positive but limited effects. For infectious diseases, the role of prolonged antibiotherapy in the management of recurrent cellulitis is well documented and new antibiotics appears for the treatment of multi resistant bacteria in infection of skin and soft tissues. Finaly, analysis of quality criteria in dermatological trial showed great capability for increase in quality, a strong prerequiste for treating our patient with safety and efficacy.
Dermatology Journal and/or Publisher
Journal Name: Annales de dermatologie et de venereologie
Journal Abbreviation: Ann Dermatol Venereol
Journal Date Published: 2013-12-24
National Center for Biotechnology Information
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/24365501
Lasted Revision: 2013-12-24
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).